Alkermes Plc (ALKS) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Total Revenue Chart for Alkermes Plc
Alkermes Plc (ALKS) revenue for FY2025 was USD 1.5B, a -5.2% change from FY2024. Alkermes Plc's revenue grew from USD 9.5M in 1991 to USD 1.5B in 2025 (15435.8% over 34 years). Earnings per share grew from USD 0.04 in 2005 to USD -0.97 in 2022 (-2716.4%). Revenue compound annual growth rate: 5-year CAGR of 7.3%, 10-year CAGR of 8.9%, 20-year CAGR of 9.5%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $6.92B
- Implied Share Price
- $41.22
- Enterprise Value
- $7.98B
- Revenue (TTM)
- $1.67B
- EBITDA
- $284.93M
- Profit Margin
- 3.97%
- Trailing P/E
- 108.47
- Forward P/E
- 133.33
- Price/Book (MRQ)
- 3.91
- Price/Sales (TTM)
- 4.15
- EV/EBITDA
- 36.62
- EV/Revenue
- 4.79
- Dividend Yield
- —
- Book Value
- $10.79
- Free Cash Flow (FY2025)
- $480.33M
- Free Cash Flow Yield
- 6.95%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.